To comprehensively evaluate subclinical organ damage of Chinese adults and its association with future cardiovascular disease and events.
To observe the significance of intervention based on digital health in preventing the onset and/or progression of subclinical organ damage and cardiovascular disease and events.
aged 18 years or older
willing to participate the study and sign informed consent
available for long-term follow-up
severe heart disease (NYHA IV)
stage 4 or 5 CKD
malignant tumors or with life expectancy less than 5 years
stroke within 3 months
All healthy subjects having cardiovascular health check-up and patients with cardiovascular diseases in the cardiovascular research clinic of our hospital are eligible for this study
Cohort
Prospective
Not listed
composite endpoint of cardiovascular events
rate of subject with myocardial infarction, stroke, heart failure, cardiovascular death
Individual cardiovascular events
rate of subject with individual components of composite endpoint
all cause mortality
rate of death
New on-set subclinical organ damage
Rate of subject with new on-set subclinical organ damage. Subclinical organ damage evaluated contains heart (left ventricular hypertrophy and diastolic dysfunction), kidneys (chronic kidney disease, microalbuminuria), vasculature (arterial stiffness, carotid plaque, intima-media thickness), and eye background (arteriosclerotic retinopathy).
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
